FGF 18 Human
(a) Analysis by RP-HPLC.
(b) Analysis by SDS-PAGE.
Description
FGF-18 Human Recombinant produced in E.coli is a single, non-glycosylated polypeptide chain containing 181 amino acids and having a molecular mass of 21.1kDa. The FGF-18 is purified by proprietary chromatographic techniques.
Product Specs
Belonging to the FGF family, which comprises at least 23 members, is fibroblast growth factor 18 (FGF18). A core 120 amino acid FGF domain in FGF18, a binding growth factor, enables a common tertiary structure. FGFs are found in limited adult tissues and are expressed during embryonic development. An essential component of calvarial and long bone development is FGF-18. Through FGFR 1c, 2c, 3c, and 4, FGF-18 signals.
A single, non-glycosylated polypeptide chain containing 181 amino acids makes up recombinant human FGF-18 generated in E.coli, which has a molecular weight of 21.1 kDa. Using specialized chromatographic methods, the FGF-18 is purified.
Reconstitute the lyophilized FGF-18 in sterile 18MΩ-cm H2O at a concentration of at least 100µg/ml, which can then be diluted further into other aqueous solutions.
Avoid freeze-thaw cycles.
(a) Analysis using RP-HPLC.
(b) Analysis by SDS-PAGE.
AEENVDFRIH VENQTRARDD VSRKQLRLYQ LYSRTSGKHI QVLGRRISAR GEDGDKYAQL LVETDTFGSQ VRIKGKETEF YLCMNRKGKL VGKPDGTSKE CVFIEKVLEN NYTALMSAKY SGWYVGFTKK GRPRKGPKTR ENQQDVHFMK RYPKGQPELQ KPFKYTTVTK RSRRIRPTHP A.
Product Science Overview
FGF-18 is a heparin-binding growth factor that stimulates the proliferation and activation of cells expressing FGF receptors . It plays a crucial role in both developing and adult organisms, predominantly in skeletal development . The protein is involved in various biological processes, including:
- Intramembranous Ossification: The process by which bone tissue is created directly from mesenchymal tissue.
- Endochondral Ossification: The process by which growing cartilage is systematically replaced by bone to form the growing skeleton.
- Angiogenesis: The formation of new blood vessels from pre-existing vessels.
- Chondrocyte Development: The development of cells that produce and maintain the cartilaginous matrix.
FGF-18 has potential clinical applications due to its role in skeletal development and regeneration. It is a putative early marker for prostate and ovarian cancer and has potential as a therapeutic target for these cancers . Additionally, recombinant human FGF-18, known as Sprifermin, is in clinical development as a potential disease-modifying osteoarthritis drug (DMOAD) . In vitro studies have shown that Sprifermin can stimulate chondrocyte proliferation and extracellular matrix production, which are essential for cartilage regeneration .
Research on FGF-18 has shown its ability to modulate extracellular matrix turnover in cartilage explants ex vivo . This modulation involves a sequential process of extracellular matrix turnover, where aggrecan degradation occurs first, followed by increased production of type II collagen and aggrecan . These chondrogenic effects are dependent on the inflammatory status of the cartilage prior to treatment .
